Lancet Publication Validates Phase 2b Induction, but Core Execution Risks Remain

What happened

Nektar Therapeutics announced publication in The Lancet of positive 16-week induction results from the Phase 2b REZOLVE-AD trial of rezpegaldesleukin in moderate-to-severe atopic dermatitis. The trial met all primary and key secondary endpoints including EASI-75, EASI-90, Itch NRS, vIGA-AD, and BSA, supporting continued development in the ongoing Phase 3 ZENITH AD program. This peer-reviewed publication provides scientific validation but does not present new efficacy data beyond what was previously reported and reflected in the stock price. The company's investment thesis remains centered on execution: confirming that Phase 3 trials started on schedule with the agreed design and that financing terms for the $300 million raise were reasonable. While the publication may modestly enhance credibility with physicians and regulators, it does not alter the binary nature of the upcoming Phase 3 readouts or the balance sheet and manufacturing risks.

Implication

The Lancet publication adds peer-reviewed rigor to the Phase 2b induction data, reinforcing the mechanism but offering no new information to re-rate the stock. Investors should shift attention to the Phase 3 ZENITH AD program: confirmation of trial initiation with FDA-aligned design and dosing is critical, as is the absence of CMC comparability issues. Financing risk remains elevated given the company's negative cash flow and lack of committed capital, so the outcome of the $300 million offering will determine near-term dilution pressure. While the publication may support scientific narrative, the market will likely require Phase 3 ITT efficacy data before granting further upside. In the meantime, maintain a WAIT rating with an attractive entry near $50 and a trim level near $95, contingent on operational milestones rather than additional Phase 2 publications.

Thesis delta

The thesis remains unchanged: the Lancet publication scientifically validates the Phase 2b induction results but does not de-risk the core execution and financing uncertainties. The WAIT rating stands as the next value inflection hinges on Phase 3 trial progress and capital market outcomes, not more Phase 2b data. Confidence in the science may improve marginally, but the binary risk profile is unaffected.